HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations
- PMID: 22431536
- DOI: 10.1309/AJCPATBZ2JFN1QQC
HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations
Abstract
International and national guidelines highlight the importance of accuracy, reproducibility, and quality control of in situ hybridization (ISH) methods for testing breast carcinomas. However, few guidelines cover the reporting of ISH cases with "unusual" signal patterns, including, eg, heterogeneity and loss of chromosome enumeration probe or gene signals. These cases are, in fact, relatively frequent, and there is a need for developing evidence- or consensus-based reporting guidelines to ensure consistency of treatment. Following an audit of cases from a single center (including >1,700 cases) we show that approximately 10% of ISH results reflect unusual signal patterns. We illustrate the most common of these patterns and provide reporting guidelines for diagnosticians and recommendations for future research. Our goal is to ensure that in the future such "rogues" are reported in a consistent manner that, ultimately, will be supported by molecular and biochemical evidence.
Similar articles
-
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods.J Clin Pathol. 2011 Aug;64(8):649-53. doi: 10.1136/jcp.2011.089847. Epub 2011 Jun 20. J Clin Pathol. 2011. PMID: 21690244
-
Quantitative analysis of diagnostic guidelines for HER2-status assessment.J Mol Diagn. 2012 May-Jun;14(3):199-205. doi: 10.1016/j.jmoldx.2012.01.012. J Mol Diagn. 2012. PMID: 22500949
-
Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity.Am J Clin Pathol. 2011 Dec;136(6):864-71. doi: 10.1309/AJCPXTZSKBRIP07W. Am J Clin Pathol. 2011. PMID: 22095371
-
Current technologies for HER2 testing in breast cancer.Crit Rev Oncol Hematol. 2011 Dec;80(3):380-92. doi: 10.1016/j.critrevonc.2010.12.005. Epub 2011 Jan 26. Crit Rev Oncol Hematol. 2011. PMID: 21273092 Review.
-
Current perspectives on HER2 testing: a review of national testing guidelines.Mod Pathol. 2003 Feb;16(2):173-82. doi: 10.1097/01.MP.0000052102.90815.82. Mod Pathol. 2003. PMID: 12591971 Review.
Cited by
-
Atypical Co-amplification with Co-localization of HER2 Gene in Breast Cancer: Combined IHC/FISH Approach as per ASCO/CAP 2018 Guidelines for Targeted Therapy Eligibility.Indian J Surg Oncol. 2024 Mar;15(1):8-11. doi: 10.1007/s13193-023-01829-2. Epub 2023 Oct 13. Indian J Surg Oncol. 2024. PMID: 38511042
-
FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations.Int J Mol Sci. 2023 Jan 10;24(2):1342. doi: 10.3390/ijms24021342. Int J Mol Sci. 2023. PMID: 36674856 Free PMC article.
-
Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: A multicenter study.Front Oncol. 2022 Sep 7;12:922185. doi: 10.3389/fonc.2022.922185. eCollection 2022. Front Oncol. 2022. PMID: 36158700 Free PMC article.
-
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells.PLoS One. 2020 Jun 11;15(6):e0234146. doi: 10.1371/journal.pone.0234146. eCollection 2020. PLoS One. 2020. PMID: 32525891 Free PMC article.
-
The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway.Oxid Med Cell Longev. 2019 May 2;2019:5470470. doi: 10.1155/2019/5470470. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31915510 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
